A031803

# Schema

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **R** |  | | | |
| **E G**  **s**I |
| . | **INDUCTION**  **Gemcitabine 2g/100mL NS intravesical** weekly during Cycles 1 & 2 **MK-3475**  **(pembrolizumab) 200mg IV** every 3 weeks during Cycles 1-4 |  | |
| . | **DISEASE ASSESSMENT\*** |
|  |
| **T** |  |  | |
| **E** |
| **R** |
|  | |

**MAINTENANCE**


**Gemcitabine 1.43g/100mL NS Intravesical** week 1 of each cycle for Cycles 5-16

**MK-3475 (pembrolizumab) 200mg IV**

every 3 weeks during Cycles 5-16

**1** Cycle = 3 weeks

\* If no evidence of disease, then patient goes onto maintenance therapy.



**OFF TREATMENT/FOLLOW-UP**

Treatment is to continue until completion of cycle, recurrence/progression or unacceptable adverse event.

Patients will be followed for 5 years from registration or until death, whichever comes first.

# Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

6

*Version Date: 05/11/2022* Update #07